武漢帝康醫(yī)藥 原料藥廠家 供應(yīng)優(yōu)質(zhì)AP26113高含量原料藥 歡迎來電

中文名稱：AP26113?

CAS號：1197958-12-5

含量：99%

分子式：C26H34ClN6O2P

分子量：529.01

作用：AP26113是一種有效的ALK抑制劑，用于ALK突變陽性的非小細胞肺癌。

存儲條件：2 year -20°C powder, 2 week 4°C in DMSO6 month -80°C in DMSO

體外研究：

AP26113 is highly active against both sensitive and resistant H3122 cells, decreasing cell growth, suppressing ALK phosphorylation and inducing apoptosis in a dose dependent manner. AP26113 decreases p-ALK in the H3122 and H3122 CR cells, with IC50 values of 7.4 versus 16.8 nM, respectively. AP26113 decreases cell number in Ba/F3 cells expressing either native or mutant EML4-ALK with IC50 of 10 nM and 24 nM, respectively. AP26113 inhibits cell growth of SU-DHL-1, H3122 and Ba/F3-EML4-ALK v1 cell lines with GI50 of 9 nM, 4 nM and 13 nM, respectively. AP26113 inhibits phosphorylation of ALK with IC50 of 3.2 nM, 1.5 nM and 2.1 nM in Karpas-299, SU-DHL-1 and L-82 cell lines. AP26113 dose-dependently inhibits phosphorylation of ALK and ERK in Karpas-299 and H3122 cells. AP26113 inhibits cell growth with IC50 of 11 nM and 16 nM in Ba/F3 line (native EML4-ALK) and Ba/F3 line (EML4-ALK G1269S mutants). AP26113 inhibits ALK phosphorylationh with IC50 of 74 nM and 335 nM in Ba/F3 line (native EML4-ALK) and Ba/F3 line (EML4-ALK E1210K mutants). AP26113 (10 mg/kg-75 mg/kg) is efficacious in PF-02341066-resistant EML4-ALK mutant mouse xenograft models. AP26113 induces regression of tumors expressing native EML4-ALK and the G1269S and L1196M mutants at 25 mg/kg, 50 mg/kg and 50 mg/kg, respectively. AP26113 inhibits EGFR phosphorylation and viability with IC50 of 75 nM and 114 nM, respectively, in Ba/F3 cells expressing EGFR-DEL. AP26113 inhibits EGFR phosphorylation and viability with IC50s of 15 and 281 nM, respectively, in Ba/F3 cells expressing EGFR-DEL/T790M. AP26113 inhibits EGFR phosphorylation with an IC50 of 62 nM and cell growth with a GI50 of 165 nM in a NSCLC line expressing EGFR-DEL (HCC827). AP26113 inhibits EGFR phosphorylation with an IC50 of 59 nM and cell growth with a GI50 of 245 nM in HCC827 cells expressing EGFR-DEL/T790M. AP26113 potently inhibits SLC34A2-ROS-driven signaling and proliferation in a dose dependent manner in HCC78 NSCLC cells.

AP26113是一種有效的ALK抑制劑，IC50為0.62 nM，可克服由于L1196M突變介導(dǎo)的Crizotinib抵抗作用。AP26113高度有效作用于敏感型和耐藥型H3122細胞，降低細胞生長，抑制ALK磷酸，并誘導(dǎo)細胞凋亡，這種作用存在劑量依賴性。AP26113作用于H3122 和 H3122 CR 細胞,降低p-ALK，IC50分別為7.4 和 16.8 nM。AP26113作用于表達野生型或突變型EML4-ALK的Ba/F3 細胞，降低細胞數(shù)，IC50分別為10 nM 和 24 nM。

FDA 授予 Ariad 肺癌藥物 AP26113 突破性治療藥物資格

武漢帝康醫(yī)藥原料有限公司，是一家專注于化工產(chǎn)品研發(fā)和生產(chǎn)的企業(yè)，竭誠為客戶提供優(yōu)質(zhì)的產(chǎn)品和服務(wù)。帝康醫(yī)藥擁有強力的研發(fā)和管理團隊嚴(yán)格把關(guān)產(chǎn)品質(zhì)量，為客戶提供人性化的服務(wù)，以及多樣化的包裝規(guī)格和優(yōu)于市場的價格。

公司始終秉承價格存之本的宗旨，以過硬的質(zhì)量和優(yōu)良的價格體系維護和拓展市場，最大限度的滿足客戶的需求。帝康醫(yī)藥，歡迎您來電來函，期待與您合作??！

AZD9291 AZD3759 ?WZ4002 ?卡博替尼 ?實驗室直供，需要的聯(lián)系